A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
Ho Yeong Lim, Jeong Heo, Hye Jin Choi, Cheng Yao Lin, Jung Hwan Yoon, Chiun Hsu, Kun Ming Rau, Ronnie T.P. Poon, Winnie Yeo, Joong Won Park, Miah Hiang Tay, Wen Son Hsieh, Christian Kappeler, Prabhu Rajagopalan, Heiko Krissel, Michael Jeffers, Chia Jui Yen, Won Young Tak
Dive into the research topics of 'A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma'. Together they form a unique fingerprint.